• DSHS HIV/STD Program

    Post Office Box 149347, MC 1873
    Austin, Texas 78714

    Phone: 737-255-4300

    Email the HIV/STD Program

    Email HIV, STD, Hepatitis C, and TB data requests to the Program - This email can be used to request data and statistics on HIV, STDs, Hepatitis C, and TB in Texas. It cannot be used to get treatment or infection history for individuals, or to request information on programs and services. Please do not include any personal, identifying health information in your email such as HIV status, Date of Birth, Social Security Number, etc.

    For treatment/testing history, please contact your local health department.

    For information on HIV testing and services available to persons living with HIV, please contact your local HIV services organization.

MAC Meeting Minutes September 13, 2013

Texas HIV Medication Advisory Committee Meeting
September 13, 2013

The September 13, 2013 meeting of the Texas HIV Medication Advisory Committee (MAC) was held at 12:10pm at 4100 Guadalupe, Building 582-West Auditorium, in Austin, Texas.

MAC Members in Attendance: Philip Keiser, M.D., Chair, Mary Paul, M.D., Yolanda Rodriguez-Escobar, Ph.D., Raul Castaneda, R.Ph., Nancy Miertschin, M.P.H., David Huse, Demetra Tennyson, Bruce Turner, Frank Rosas

DSHS Staff in Attendance: Shelley Lucas, Felipe Rocha, Lisa Cornelius, Rachel Sanor, Dan Warr, John Allen, Kurt Wolf, Mary Richards, Evelyn Shewmaker

Registered Guests: Becky Gonzales, Jack McClure, Tyler Hunter, Tom Valentine, John Fuchs, Suzanne Erickson, Jesse Jones, Linda Robasser, Anthony DeLeon, Linda Cantu, Mork Vane, David Poole, Randy Clark, Michelle Flores, Sunnye Simmons, Douglas Ford, Victoria Ford, Sylvia Moreno, Ray Moore, Jay Dee Fredricksen

Action and Discussion Items Covered:

  1. The meeting was called to order by Dr. Keiser at 12:10 pm, September 13, 2013

  2. The committee reviewed and unanimously approved the January 18, 2013 meeting minutes.

  3. Felipe Rocha, Manager of the TB/HIV/STD Viral Hepatitis Unit, introduced Rachel Sanor as the new Manager for the Texas HIV Medication Program, and Shelley Lucas as the new Branch Manager for HIV/STD Prevention and Care.

  4. Felipe Rocha also introduced Janna Zumbrun in absentia as the new Assistant Commissioner for Disease Control and Prevention.

  5. The update on the Division for Disease Control and Prevention Services was removed from the day’s agenda.

  6. Felipe Rocha presented an update on the THMP Budget, explaining that the update serves as a momentary snapshot in time and therefore subject to revision as additional data on revenue, utilization and funding becomes available for the fiscal year. He mentioned that a request has been made to utilize some of the SPAP rebate funds received towards the development or enhancement of integrated data systems, but a timeline has not been established for when the request may be considered or approved. There are concerns that the incoming rebates may be greatly diminished or depleted as the Affordable Care Act becomes fully implemented heading into 2015. He stated that a pilot program called the Texas Insurance Assistance Program (TIAP) is currently underway to provide wraparound care with insurance premiums, copayments and deductibles for specific THMP enrollees, with approximately 20 clients enrolled to date. It’s too soon to have estimates on expenditures and utilization for the TIAP, but once they are available they will be examined closely to determine viability as an ongoing program within the THMP alongside traditional Texas ADAP and the Medicare SPAP.

  7. Rachel Sanor presented ADAP/SPAP update reports detailing clients served by month, first time enrollees by month, medication expenditures and the top ten drugs by cost for State Fiscal year 2013. She explained that recent refinements in application screening methods has decreased the turnaround time for approval of incoming applications to around four weeks, and hopes to see that timeframe further reduced as the screening procedure is refined.

  8. John Fuchs, Pharm D, gave a presentation on the integrase inhibitor Tivicay (dolutegravir) from ViiV Healthcare, which was recently approved by the FDA. The Committee unanimously approved the recommendation that the Commissioner of Health approve the addition of Tivicay to the THMP formulary.

  9. The representative from Salix was unable to attend the meeting, so Dr. Keiser spoke briefly about their medication Fulyzaq. Dr. Keiser recommended that the Committee table discussion on the medication until further information was available. The Committee agreed to table the discussion. Dr. Mary Paul mentioned that she has questions regarding pregnancy and fetal harm in relation to the drug that should be addressed.

  10. The next MAC meeting was scheduled for January 31, 2014, from 12pm-3pm.

  11. There were no public comments.

  12. The meeting was adjourned by Dr. Keiser at 1:12 pm.

Approved by:
Phillip H. Keiser, M.D. – Chairman, Texas HIV Medication Advisory Committee

Last updated June 11, 2020